Home >> Marketplace Archives >> Prometheus Labs launches IBD, liver tests, 12/17

Prometheus Labs launches IBD, liver tests, 12/17

Print Friendly, PDF & Email

 

December 2017—Prometheus Laboratories introduced Prometheus Monitr Crohn’s Disease, a serum test that measures and monitors mucosal healing status in Crohn’s disease patients. The test can be used as an adjunct to endoscopy or by itself, between endoscopies, allowing for more frequent, noninvasive monitoring.

The clinical validation of the Mon­itr test demonstrated high accuracy and concordance rates with endoscopically visualized mucosal disease activity in adult Crohn’s disease patients, regardless of the anatomical disease location or selected treatment regimens. Monitr will allow health care providers to more easily evaluate Crohn’s disease patients who have suspected active disease in difficult-to-reach locations, such as the small bowel. The test report provides a single objective Mucosal Healing Index Score that can be used to assess and track disease activity over time.

Prometheus also introduced the Fibro­Spect NASH test, a tool to help health care providers stratify nonalcoholic steatohepatitis, or NASH, patients by risk, based on the severity of their liver fibrosis. NASH is a potentially serious condition that is related to the more common and less severe nonalcoholic fatty liver disease.

Prometheus Laboratories, 888-423-5227

X